Gastrointestinal symptoms began in the ‘wash out’ period changing from adalimumab, an anti-TNF inhibitor that is used to treat IBD, to tocilizumab, an IL-6 inhibitor which has been reported to aggravate underlying or undiagnosed IBD (3). Here, IL6 is linked to irritable bowel syndrome.